Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949988 · ClinicalTrials.gov registry record · Phase 1
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00949988: Clinical Trial Phase 1 study, sponsored by University of California, San Diego.
NCT00949988 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949988, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label phase I/II study that will investigate the combination of dasatinib and rituximab therapy in patients with relapsed/refractory CLL. In phase I, eligible subjects will take either 100 mg or 140 mg of dasatinib daily along with rituximab on day 1 of each cycle for 6 cycles. In phase II, eligible subjects will all receive the same dose of dasatinib, as established in the phase I portion, along with rituximab on day 1 of each cycle for 6 cycles. The investigators hypothesize that the combination of dasatinib and rituximab will demonstrate efficacy in the treatment of patients with relapsed/refractory CLL.
Interventions
- DRUG Dasatinib and Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Why NCT00949988 stopped before completion
NCT00949988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Dasatinib and Rituximab is the first listed.
NCT00949988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00949988 about?
NCT00949988 is a clinical study titled "A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia". This is an open-label phase I/II study that will investigate the combination of dasatinib and rituximab therapy in patients with relapsed/refractory CLL. In phase I, eligible subjects will take either 100 mg or 140 mg of dasatinib daily along with rituximab on day 1 of each cycle for 6 cycles. In ph...
What is the current status of trial NCT00949988?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00949988?
The interventions under investigation include: Dasatinib and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00949988?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00949988's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia